Avigen to Present at Roth Capital Annual Growth Stock Conference
18 February 2004 - 1:28AM
PR Newswire (US)
Avigen to Present at Roth Capital Annual Growth Stock Conference
Company's Webcast to Provide Update on Strategic Programs DANA
POINT, Calif., Feb. 17 /PRNewswire-FirstCall/ -- Avigen, Inc.
announced today that its presentation at the Roth Capital Partners
Growth Stock Conference, both audio and slides, will be webcast
live today, Tuesday, February 17, 2004, at 12:00 p.m. Pacific Time.
Avigen's Chief Executive Officer, John Monahan, Ph.D., will provide
an update on the company's development programs for DNA-based drugs
for serious chronic conditions, such as hemophilia-B, Parkinson's
disease and neuropathic pain. The presentation will be broadcast
live via the Web and archived for 30 days, accessible from the
following link: http://www.vcall.com/CEPage.asp?ID=86047 or by
visiting Avigen's web site at http://www.avigen.com/. About Avigen
Avigen, Inc., based in the San Francisco Bay Area, focuses on the
development of DNA-based drugs for serious chronic conditions.
Avigen's proposed gene delivery products are designed for direct
administration to patients in order to achieve expression of
therapeutic proteins within the body. The company is actively
enrolling subjects in its clinical trial for Coagulin-B(R),
Avigen's Factor IX gene therapy product for hemophilia B, currently
being conducted at the Children's Hospital of Philadelphia,
Stanford University Medical Center and the University of
Pittsburgh. Patients or physicians who would like more information
about enrollment criteria andthe study should contact Avigen's
Clinical Development Department at or call 1-877-4-AVIGEN
(877-428-4436). Additional information on Avigen's proprietary gene
delivery products can be found at http://www.avigen.com/ About the
Roth Capital Partners 16th Annual Growth Stock Conference This
annual event is the largest in the nation for emerging growth
companies. It provides a concentrated forum where Institutional
Investors can meet the executives of growth companies hand picked
by Roth Capital's research team. The conference will highlight
approximately 225 companies from industry groups, including Health
Care, Consumer Products, Technology, and Financial Services. This
year, as a result of numerous client requests, Roth has extended
the conference to three working days, including a Discovery Day,
which will highlight companies "undiscovered" by Wall Street. For
more information about the conference visit
http://www.apgweb.com/roth/danapoint/ . Investors Please Note: The
statements in this news release regarding Avigen's clinical trial
and the potential of gene therapy are forward-looking statements.
Actual results may differ materially from current expectations due
to a variety of factors, including the difficulty of obtaining
required regulatory approvals. In addition, there are many other
risks and uncertainties inherent in the development of gene therapy
products. Other risks relating to Avigen are detailed in Avigen's
Quarterly Report on Form 10-Q for the period ended September 30,
2003, under the caption "Risk Factors" in Item 2 of Part 1 of that
report, which was filed with the SEC on November 13, 2003.
DATASOURCE: Avigen, Inc. CONTACT: Thomas J. Paulson, Chief
Financial Officer of Avigen, Inc., +1-510-748-7150, or fax,
+1-510-748-7155, or Web site: http://www.avigen.com/
Copyright
Avigen (MM) (NASDAQ:AVGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Avigen (MM) (NASDAQ:AVGN)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Avigen (MM) (NASDAQ): 0 recent articles
More Avigen, (MM) News Articles